Dapagliflozin in Depression

Recruiting now · Phase 1/Phase 2

Conditions studied: Depression

In brief

Major depressive disorder (MDD) is currently one of the leading causes of disability and suicidal death worldwide, and despite extensive research and massive improvements in mental health, the nature of MDD remains ambiguous. Moreover, about two-thirds of MDD patients fail to optimally respond to currently available standard therapies, and many of them suffer from treatment-resistant depression

Key facts

Study ID

NCT07239011

Run by

Tanta University

People needed

60

Starts

2025-11-01

Expected to finish

2026-12-20

Last updated by the study team

2025-11-25

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years Both male and female will be included Negative pregnancy test and effective contraception. Depressed patients for at least 2 months with Hamilton rating score more than 18.

You may not qualify if…

• Patients with bipolar I or bipolar II disorder, personality disorders, and eating disorders.
• Patients with substance dependence or abuse Patients with history of seizures or receiving electroconvulsive therapy (ECT) Patients with inflammatory disorders Patients with allergy or contraindications to the used medications Patients with finally pregnant or lactating females Diabetic patients Sever kidney disorders

Where it is running

• Mostafa Bahaa — Damietta, New Damietta, Egypt (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.